Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (Q3)Sep 30, 2025 | (Q2)Jun 30, 2025 | (Q1)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | -195.53%-549.1K | -73.24%-274.84K | 7,406.39%72.04K | 0.09%-817.61K | -172.09%-472.17K | 55.57%-185.8K | 4.08%-158.65K | 98.39%-986 | 48.93%-818.37K | 31.40%-173.53K |
| Net income from continuing operations | 82.43%-36.17K | 470.90%640.85K | -6.09%-159.92K | 21.77%-809.23K | -119.67%-279.83K | 49.16%-205.88K | 36.11%-172.78K | 34.95%-150.74K | -7.98%-1.03M | 27.53%-127.39K |
| Operating gains losses | ---- | ---500K | ---- | ---10.5K | ---- | ---- | ---- | ---- | ---- | ---- |
| Remuneration paid in stock | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- | --52.11K | ---- |
| Unrealized gains and losses of investment securities | ---222K | ---274K | --2K | --1.5K | --1.5K | --0 | --0 | --0 | --0 | ---- |
| Remuneration paid in stock | ---- | ---- | ---- | --0 | --0 | --0 | --0 | --0 | 64.09%44.28K | -94.08%1.6K |
| Other non cashItems | -2,370.61%-262.43K | ---- | ---- | 10.87%-63.68K | -381.41%-39.09K | 72.14%-10.62K | 64.48%-8.69K | 76.78%-5.28K | 80.21%-71.45K | 110.62%13.89K |
| Change In working capital | -192.86%-28.51K | -720.78%-141.69K | 48.33%229.96K | -66.36%64.31K | -26.82%-144.25K | 40.20%30.7K | -76.42%22.83K | -16.74%155.03K | 161.58%191.18K | -526.34%-113.74K |
| -Change in receivables | -2,491.11%-29.15K | 1,281.31%3.99K | 16.02%222.52K | 12.58%-30.35K | -50.46%-221.3K | 97.02%-1.13K | 106.50%289 | 24.11%191.79K | 77.49%-34.71K | -1,276.76%-147.08K |
| -Change in prepaid assets | -19.85%-14.98K | -25.69%2.99K | -73.06%1.96K | -96.28%6.33K | -86.83%7.54K | -283.73%-12.5K | -89.13%4.03K | -89.47%7.26K | 191.88%170.08K | -30.15%57.29K |
| -Change in payables and accrued expense | -64.75%15.63K | -903.18%-148.68K | 112.47%5.49K | 58.23%88.32K | 390.20%69.5K | -16.08%44.32K | -71.19%18.51K | -18.03%-44.02K | 93.34%55.81K | 46.37%-23.95K |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | -195.53%-549.1K | -73.24%-274.84K | 7,406.39%72.04K | 0.09%-817.61K | -172.09%-472.17K | 55.57%-185.8K | 4.08%-158.65K | 98.39%-986 | 48.93%-818.37K | 31.40%-173.53K |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 75K | 0 | 0 | 0 | 0 | -90K | 0 | |||
| Net PPE purchase and sale | ---- | --75K | ---- | --0 | --0 | --0 | --0 | ---- | ---90K | --0 |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | ---- | --75K | ---- | --0 | --0 | --0 | --0 | ---- | ---90K | --0 |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 431.07%876.27K | 310.65K | 0 | -27.77%642.95K | 147.54%457.95K | 165K | 0 | 20K | 49.54%890.11K | 48.59%185K |
| Net common stock issuance | 317.79%689.35K | --310.65K | --0 | -6.23%642.95K | 147.54%457.95K | --165K | --0 | --20K | 56.20%685.7K | 48.59%185K |
| Proceeds from stock option exercised by employees | --189.98K | ---- | ---- | --0 | --0 | --0 | --0 | ---- | 39.09%217.33K | --0 |
| Net other financing activities | ---3.06K | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---12.92K | --0 |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 431.07%876.27K | --310.65K | --0 | -27.77%642.95K | 147.54%457.95K | --165K | --0 | --20K | 49.54%890.11K | 48.59%185K |
| Net cash flow | ||||||||||
| Beginning cash position | 203.72%220.4K | -52.60%109.59K | -82.31%37.55K | -7.92%212.21K | -74.21%51.77K | -88.46%72.57K | 36.65%231.22K | -7.92%212.21K | -81.38%230.46K | -44.07%200.74K |
| Current changes in cash | 1,672.86%327.17K | 169.84%110.81K | 278.88%72.04K | -856.66%-174.66K | -224.00%-14.22K | 95.14%-20.8K | -134.51%-158.65K | 131.04%19.01K | 98.19%-18.26K | 108.93%11.47K |
| End cash Position | 957.78%547.57K | 203.72%220.4K | -52.60%109.59K | -82.31%37.55K | -82.31%37.55K | -74.21%51.77K | -88.46%72.57K | 36.65%231.22K | -7.92%212.21K | -7.92%212.21K |
| Free cash from | -195.53%-549.1K | -73.24%-274.84K | 7,406.39%72.04K | 9.99%-817.61K | -172.09%-472.17K | 56.61%-185.8K | 35.35%-158.65K | 98.39%-986 | 43.31%-908.37K | 31.40%-173.53K |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.